146 related articles for article (PubMed ID: 26078798)
1. A MicroRNA Expression Signature In Taxane-anthracycline-Based Neoadjuvant Chemotherapy Response.
Zheng Y; Li S; Boohaker RJ; Liu X; Zhu Y; Zhai L; Li H; Gu F; Fan Y; Lang R; Liu F; Qian X; Xu B; Fu L
J Cancer; 2015; 6(7):671-7. PubMed ID: 26078798
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in microRNA let-7 binding sites of the
Du Y; Zhou L; Lin Y; Yin K; Yin W; Lu J
Ann Transl Med; 2019 Apr; 7(7):138. PubMed ID: 31157259
[TBL] [Abstract][Full Text] [Related]
4. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
[TBL] [Abstract][Full Text] [Related]
5. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C
Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239
[TBL] [Abstract][Full Text] [Related]
6. Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience.
Matthews CM; Nymberg K; Berger M; Vargo CA; Dempsey J; Li J; Ramaswamy B; Reinbolt R; Sardesai S; Wesolowski R; Williams N; Lustberg M
J Oncol Pharm Pract; 2020 Apr; 26(3):572-579. PubMed ID: 31256745
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Bao H; Yu D; Wang J; Qiu T; Yang J; Wang L
Anticancer Drugs; 2008 Mar; 19(3):317-23. PubMed ID: 18510179
[TBL] [Abstract][Full Text] [Related]
8. Plasma exosomal microRNA-125b as a monitoring biomarker of resistance to mFOLFOX6-based chemotherapy in advanced and recurrent colorectal cancer patients.
Yagi T; Iinuma H; Hayama T; Matsuda K; Nozawa K; Tsukamoto M; Shimada R; Akahane T; Tsuchiya T; Ozawa T; Hashiguchi Y
Mol Clin Oncol; 2019 Oct; 11(4):416-424. PubMed ID: 31497299
[TBL] [Abstract][Full Text] [Related]
9. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
Xu L; Che X; Wu Y; Song N; Shi S; Wang S; Li C; Zhang L; Zhang X; Qu X; Teng Y
Oncol Rep; 2018 May; 39(5):2315-2323. PubMed ID: 29565454
[TBL] [Abstract][Full Text] [Related]
10. A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Wu L; Yao L; Zhang H; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Yin CC; Xie Y
Oncotarget; 2016 Jan; 7(4):5042-52. PubMed ID: 26573232
[TBL] [Abstract][Full Text] [Related]
11. Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2.
Wang XX; Ye FG; Zhang J; Li JJ; Chen QX; Lin PY; Song CG
Cancer Manag Res; 2018; 10():4393-4400. PubMed ID: 30349372
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
13. A multifactorial 'Consensus Signature' by
Turner N; Forcato M; Nuzzo S; Malorni L; Bicciato S; Di Leo A
NPJ Breast Cancer; 2015; 1():15003. PubMed ID: 28721363
[TBL] [Abstract][Full Text] [Related]
14. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
15. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Nabholtz JM; Abrial C; Mouret-Reynier MA; Dauplat MM; Weber B; Gligorov J; Forest AM; Tredan O; Vanlemmens L; Petit T; Guiu S; Van Praagh I; Jouannaud C; Dubray-Longeras P; Tubiana-Mathieu N; Benmammar KE; Kullab S; Bahadoor MR; Radosevic-Robin N; Kwiatkowski F; Desrichard A; Cayre A; Uhrhammer N; Chalabi N; Chollet P; Penault-Llorca F
Ann Oncol; 2014 Aug; 25(8):1570-7. PubMed ID: 24827135
[TBL] [Abstract][Full Text] [Related]
16. Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy.
Jiang C; Wu S; Jiang L; Gao Z; Li X; Duan Y; Li N; Sun T
PeerJ; 2019; 7():e7515. PubMed ID: 31534839
[TBL] [Abstract][Full Text] [Related]
17. SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.
Collie-Duguid ES; Sweeney K; Stewart KN; Miller ID; Smyth E; Heys SD
Breast Cancer Res Treat; 2012 Apr; 132(3):807-18. PubMed ID: 21695460
[TBL] [Abstract][Full Text] [Related]
18. Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer.
Rašić A; Sofić A; Bešlija S; Rašić I; Hasanbegović B
Med Glas (Zenica); 2019 Feb; 16(1):77-82. PubMed ID: 30256061
[TBL] [Abstract][Full Text] [Related]
19. Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients.
Luo Y; Wang X; Niu W; Wang H; Wen Q; Fan S; Zhao R; Li Z; Xiong W; Peng S; Zeng Z; Li X; Li G; Tan M; Zhou M
Oncol Lett; 2017 Feb; 13(2):867-874. PubMed ID: 28356971
[TBL] [Abstract][Full Text] [Related]
20. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
